Please login to the form below

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

Gilead strikes deal with NHS England on CAR-T Yescarta

Today’s agreement will see around 200 adult patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma be eligible for treatment. ... Not far behind Yescarta in the NICE process in DLBCL is Novartis’Kymriah.

Latest news

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness. ... population in Europe, which could give Gilead space to establish itself in DLBCL in these markets.
Gilead optimistic about Yescarta deal in UK

The CAR-T production process. DLBCL will be the competitive battleground for Novartis and Gilead, and there’s no doubt Yescarta has the upper hand at this early stage. ... It has significantly better response rates in DLBCL than Kymriah: its overall
Novartis’ CAR-T Kymriah gets green light in England

at the same time as Kymriah in Europe for adults with DLBCL and primary mediastinal large B-cell lymphoma (PMLBL). ... That might suggest Novartis will have a tougher time when it comes to the adult DLBCL indication for Kymriah.
Novartis and Gilead's rival CAR-Ts approved in Europe, but supply capacity in question

in second or later relapse, and also for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ... Nevertheless, Novartis’staggered roll-out gives Gilead a free run at the DLBCL market for the time being.
It’s a no for Yescarta, says NICE on heels of EU approval

mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.”It’s been estimated there are around 4, 800 people are diagnosed with DLBCL or PMLBL each year

More from news
Approximately 6 fully matching, plus 40 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
Deal Watch January 2018

The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl
Pharma deals in April 2015

its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
Current development and marketing of biosimilar monoclonal antibodies in Latin America

Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Celgene boosts CAR-T stake again with Bluebird Bio deal

That deal gave it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene maraleucel), which is in testing for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), as

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Director, Market Access / HEOR - North-West: Negotiable

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Consultant Health Economics - London / Oxford: Negotiable

Senior Medical Writer: Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Consumer Health Account Director: Circa £60, 000 Gym and More

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Associate Director: £75, 000-90, 000

Senior Account Manager: Negotiable

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Scientific Director / Editorial Team Leader: Great salary and benefits

Medical Writers: Competitive Salary and Benefits

Production Manager – Healthcare Communications: DOE

Associate Medical Director: Highly Competitive

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Associate Editorial Director – Med Comms – London: Salary TBC

Senior Medical Writer: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Account Director: £48, 000 - £60, 000

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Events Manager – Med Comms – Surrey: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...